In a dramatic late-session move on Wednesday, shares of Advanced Biomed Inc. (NASDAQ: ADVB) skyrocketed 74.6% to $12.36, following the company's decision to terminate a $25 million equity line agreement. The facility, which was more than double the company's preliminary market capitalization as of Tuesday, had been a source of concern for investors worried about potential dilution.
The terminated equity facility represented 2.1 times the estimated market value of the company based on Tuesday's closing price. With 1,652,133 shares outstanding as of May 29 and a Tuesday close of $7.08, the implied market cap stood at approximately $11.7 million. By Wednesday afternoon, the surge in share price pushed the market value to roughly $20.4 million.
Trading activity was exceptionally heavy, with volume reaching 27.8 million shares as of 14:55 EDT—16.8 times the most recent reported share count. The stock touched an intraday high of $18.07 before pulling back, trading 31.6% below that peak by late afternoon. The broader market was modestly lower, with the SPDR S&P Biotech ETF (XBI) declining 1.1% and the iShares Russell 2000 ETF (IWM) dropping 0.8%.
The equity facility, which allowed Advanced Biomed to sell up to $25 million in shares to Helena Global, expired on July 21. According to regulatory filings, no shares were ever sold under the agreement, though commitment-fee shares had been previously issued. CEO Xiaomin Chen signed a withdrawal letter on July 20, stating the company had “determined not to proceed with the offering… at this time.” The associated share registration was also retracted.
The termination eliminates the possibility of future share issuance under the facility, removing a key overhang that had weighed on the stock. While it also cuts off an optional source of cash, Wednesday's market reaction suggests investors prioritized the former impact. The company had been operating under a going-concern warning as of its March-quarter report, and the loss of this financing option adds to its limited capital-raising avenues.
Advanced Biomed has undergone a significant strategic shift in recent months. In April, the company acquired Acellent Technologies for 270,000 shares valued at $1.08 million, redirecting its primary focus from life sciences to artificial intelligence. Subsequently, Advanced Biomed announced plans to divest its Taiwan biomedical division for $490,000 as of June 30, a transaction expected to close within the next three months. The division oversees biomedical research featuring the A+PerfusC 3D cell-culture platform.
The company's most recent quarterly results, for the period ended March 31, do not yet reflect the Acellent acquisition. The March quarter reported a loss of $488,942 from continuing operations, with cash from continuing operations totaling $2.60 million. Risks remain elevated: the Taiwan sale has not yet closed, there is no complete quarter of reported AI activity, and the discontinuation of the equity line further constrains financing flexibility.
